NCT03838367: A trial that was reported late by CytoDyn, Inc.
This trial has reported, although it was 695 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03838367 |
|---|---|
| Title | A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 22, 2019 |
| Completion date | July 15, 2022 |
| Required reporting date | July 15, 2023, midnight |
| Actual reporting date | June 9, 2025 |
| Date last checked at ClinicalTrials.gov | June 12, 2026 |
| Days late | 695 |